In a report released yesterday, Elemer Piros from Cantor Fitzgerald reiterated a Buy rating on Bellicum Pharmaceuticals (NASDAQ: BLCM), with a price target of $18. The company’s shares closed yesterday at $6.06, close to its 52-week low of $5.02.
According to TipRanks.com, Piros has 0 stars on 0-5 star ranking scale with an average return of -8.3% and a 39.1% success rate. Piros covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Strongbridge Biopharma Plc, and Global Blood Therapeutics.
Currently, the analyst consensus on Bellicum Pharmaceuticals is a Moderate Buy with an average price target of $16.
See today’s analyst top recommended stocks >>
The company has a one-year high of $13.30 and a one-year low of $5.02. Currently, Bellicum Pharmaceuticals has an average volume of 640.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. It uses its proprietary chemical induction of dimerization that controls components of the immune system in real time.
